Review



low-dose il-2  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Thermo Fisher low-dose il-2
    Low Dose Il 2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/low-dose il-2/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    low-dose il-2 - by Bioz Stars, 2026-03
    90/100 stars

    Images



    Similar Products

    low dose il7  (R&D Systems)
    98
    R&D Systems low dose il7
    Low Dose Il7, supplied by R&D Systems, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/low dose il7/product/R&D Systems
    Average 98 stars, based on 1 article reviews
    low dose il7 - by Bioz Stars, 2026-03
    98/100 stars
    		  Buy from Supplier
    low-dose il-2 aldesleukin  (Clinigen Inc)
    90
    Clinigen Inc low-dose il-2 aldesleukin
    Low Dose Il 2 Aldesleukin, supplied by Clinigen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/low-dose il-2 aldesleukin/product/Clinigen Inc
    Average 90 stars, based on 1 article reviews
    low-dose il-2 aldesleukin - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    low-dose il-2  (Thermo Fisher)
    90
    Thermo Fisher low-dose il-2
    Low Dose Il 2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/low-dose il-2/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    low-dose il-2 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    low-dose il-2  (PeproTech)
    90
    PeproTech low-dose il-2
    Low Dose Il 2, supplied by PeproTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/low-dose il-2/product/PeproTech
    Average 90 stars, based on 1 article reviews
    low-dose il-2 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    low dose rh il-2  (R&D Systems)
    90
    R&D Systems low dose rh il-2
    Low Dose Rh Il 2, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/low dose rh il-2/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    low dose rh il-2 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    low-dose il-2  (Biohaven Pharmaceuticals)
    90
    Biohaven Pharmaceuticals low-dose il-2
    Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use <t>of</t> <t>IL-2</t> and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.
    Low Dose Il 2, supplied by Biohaven Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/low-dose il-2/product/Biohaven Pharmaceuticals
    Average 90 stars, based on 1 article reviews
    low-dose il-2 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    low-dose il-2 aldesleukin  (Novartis)
    90
    Novartis low-dose il-2 aldesleukin
    Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use <t>of</t> <t>IL-2</t> and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.
    Low Dose Il 2 Aldesleukin, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/low-dose il-2 aldesleukin/product/Novartis
    Average 90 stars, based on 1 article reviews
    low-dose il-2 aldesleukin - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    low-dose il- 2 cyt- 370  (ProSpec)
    90
    ProSpec low-dose il- 2 cyt- 370
    Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use <t>of</t> <t>IL-2</t> and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.
    Low Dose Il 2 Cyt 370, supplied by ProSpec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/low-dose il- 2 cyt- 370/product/ProSpec
    Average 90 stars, based on 1 article reviews
    low-dose il- 2 cyt- 370 - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use of IL-2 and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.

    Journal: International Journal of Molecular Sciences

    Article Title: Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond

    doi: 10.3390/ijms24010204

    Figure Lengend Snippet: Strategies to promote anti-tumor effector function for NK cell immunotherapy. (1) NK cell engagers include bispecific (BiKEs) and trispecific antibodies (TRiKEs) that bring tumor antigens and supportive cytokines into proximity with NK cell receptors. (2) Supportive cytokine-mediated approaches include the use of IL-2 and IL-15 to promote NK cell expansion and cytotoxicity. (3) Impairing TGF-β signaling and preventing buildup of adenosine in the tumor microenvironment can reduce local suppressive effects on NK cells. (4) Blockade of immune checkpoints (PD-1, PD-L1, CTLA4) and inhibitory NK receptors (KIR2D) may circumvent NK exhaustion and improve anti-tumor function. (5) The addition of monoclonal antibodies and engineering of high affinity CD16 receptors promote the CD16-Fc ligand binding interaction, leading to enhanced ADCC. (6) Engineered selective antigen receptors such as CARs and TCRs can redirect NK cells towards specified tumor antigens and increase cytotoxicity. NK: natural killer, BiKE: bispecific killer engagers, TRiKE: trispecific killer engagers, Ag: antigen, NKG2D: natural killer group 2 member D, IL: interleukin, TGF-β: transforming growth factor beta, AMP: adenosine monophosphate, PD-1: programmed cell death protein 1, CTLA-4: cytotoxic T-lymphocyte associated protein 4, KIR2D: killer immunoglobulin-like receptor group 2 member D; PD-L1: programmed death-ligand 1, ADCC: antibody-dependent cellular cytotoxicity, TCR: T cell receptor, CAR: chimeric antigen receptor. Created with BioRender.

    Article Snippet: I/II , Biohaven Pharmaceuticals , Autologous memory-like NK cells with BHV-1100 (antibody recruiting molecule) and low-dose IL-2 , MM , NCT04634435.

    Techniques: Ligand Binding Assay